12:00 AM
Sep 22, 2016
 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Hemoglobin subunit γ 1 (HBG1); HBG2; CRISPR-associated protein 9 (Cas9)


INDICATION: Sickle cell disease (SCD)

Patient sample and cell culture studies suggest enhancing fetal hemoglobin production in hematopoietic stem and progenitor cells (HSPCs) using CRISPR-based gene editing could help treat...

Read the full 123 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >